Physician profile
Travis Kotter
NPI 1457746844
$766.65
in general payments reported to CMS, 2019-2025
26 companies · $30.80 in 2025
The $30.80 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.81 · 2020: $86.06 · 2021: $197 · 2022: $155 · 2023: $181 · 2024: $63.52 · 2025: $30.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $82.26 | 2023-2024 | Accolade Sr |
| Stryker Corporation | $65.06 | 2019-2025 | Citrefix |
| Hologic Sales and Service, LLC | $60.81 | 2022-2023 | Thinprep 2000 Processor, Aptima |
| Biohaven Pharmaceuticals, INC. | $50.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.45 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $37.57 | 2021-2023 | Strensiq |
| Active Medical, LLC | $32.14 | 2019 | |
| Scilex Pharmaceuticals INC. | $29.31 | 2020 | |
| Smith+Nephew, INC. | $27.10 | 2021-2023 | Evos |
| Astellas Pharma US INC | $25.43 | 2023 | Veozah |
| Orthofix Medical, INC. | $25.00 | 2022 | |
| Mimedx Group, INC. | $24.80 | 2024 | |
| Horizon Therapeutics Plc | $22.25 | 2023 | Krystexxa |
| Nevro Corp. | $19.43 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.42 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.40 | 2021 | |
| Neurocrine Biosciences, INC. | $18.42 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.39 | 2021 | |
| Medtronic, INC. | $16.65 | 2022 | |
| Paragon 28, INC. | $15.06 | 2020 | |
| Dexcom, INC. | $13.35 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $13.32 | 2020 | |
| Daiichi Sankyo INC. | $13.16 | 2020 | |
| Amgen INC. | $12.24 | 2022 | |
| Merck Sharp & Dohme LLC | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Kotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.